916913-30-9

Upstream product

• 689283-23-6 3-[1-methyl-2(RS_S)-phenylsulfinyl-(1S)-ethyl]-(2S,3R)-oxiran-2-ylmethanol 
• 916913-17-2 (2R,3S,4S)-1-tert-butyldimethylsilyloxy-2,4-dimethyl-5-phenylsulfinylpentan-3-ol 
• 916913-15-0 (2R,3S,4S)-2,4-dimethyl-5-phenylsulfinylpentane-1,3-diol 
• 916913-29-6 (2R,3R,4R)-3-benzoyloxy-1-tert-butyldiphenylsilyloxy-5-tert-butyldimethylsilyloxy-2,4-dimethylpentan-1-ol 
• 916913-28-5 (2R,3R,4R)-3-benzoyloxy-5-tert-butyldimethylsilyloxy-2,4-dimethylpentan-1-ol 

Downstream Products

• 916913-32-1 (2R,3R,4R,5S)-3-benzoyloxy-1-tert-butyldiphenylsilyloxy-2,4-dimethyloctadecan-5-ol 
• 916913-33-2 (2R,3R,4R,5S)-tert-butyldiphenylsilyloxy-2,4-dimethyloctadecane-3,5-diol 

Relevant academic research and scientific papers

Stereoselective synthesis of the enantiomer of the fatty acid component of the potent immunosuppressant, stevastelin

A stereoselective synthesis of the enantiomer of the fatty acid chain of stevastelin is disclosed. The C4 methyl group is introduced regio- and stereoselectively via dimethylcuprate opening of epoxy alcohol while the C5 stereogenic center was introduced i